CN103341215B - A kind of antibacterial anti-adhesion material and preparation method thereof - Google Patents
A kind of antibacterial anti-adhesion material and preparation method thereof Download PDFInfo
- Publication number
- CN103341215B CN103341215B CN201310219258.6A CN201310219258A CN103341215B CN 103341215 B CN103341215 B CN 103341215B CN 201310219258 A CN201310219258 A CN 201310219258A CN 103341215 B CN103341215 B CN 103341215B
- Authority
- CN
- China
- Prior art keywords
- present
- preparation
- sodium chloride
- adhesion material
- electrolysis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of antibacterial anti-adhesion material and preparation method thereof.This material comprises following composition: guluronic acid, mannuronic acid, sodium hypochlorite, hypochlorous acid, active oxygen, sodium chloride, water.Compared with prior art, the present invention is because sterilizing by spectrum, and degraded completely, can be utilized by body absorption, be free from side effects to health, use safety.
Description
Technical field
The present invention relates to a kind of medical material, particularly relate to a kind of antibacterial anti-adhesion material and preparation method thereof.
Background technology
At present, mostly the antibiotic preparation on market is that chemical synthetic drug is as antibiotic, and a large amount of life-time service can produce bacterial drug resistance; Disinfection product is as chlorhexidine acetate, quaternary ammonium salt, nanometer silver class preparation, and these are all external sterilizing preparations, is not useable for wound surface in body and uses, and very easily produce untoward reaction; The anti-inflammation formulation of Chinese medicine extraction is because of extraction process complexity, and extract component is uncertain, is difficult to accomplish monomer purification, produces, bring very large life danger to patient so often have untoward reaction.In recent years, be the antibacterial medical product of main material in addition with chitosan, as chitosan antiblocking liquor or film.But because be extract from the shell of animal, the protein ingredient of the inside is difficult to remove, and molecular weight is also difficult to control, and occurs so often have untoward reaction.
Summary of the invention
Technical problem to be solved by this invention is the preparation method providing a kind of antibacterial anti-adhesion material.The method adopts soluble alginate and sodium chloride mixed liquor, and the liquid preparation containing guluronic acid, mannuronic acid, sodium hypochlorite, hypochlorous acid, active oxygen, sodium chloride prepared by film electrolysis tech, makes it have the effect of antiseptic anti-adhesion.
The present invention one of is intended to solve the problems of the technologies described above at least to a certain extent or at least provides a kind of useful business to select.
The present invention be intended to solve prior art problem one of at least.One aspect of the present invention provides a kind of antibacterial anti-adhesion material, comprises following composition: guluronic acid, mannuronic acid, sodium hypochlorite, hypochlorous acid, active oxygen, sodium chloride, water.
According to the concrete example of the present invention, comprise the composition of following mass percent, guluronic acid 0.1%-10%, mannuronic acid 0.1%-10%, sodium hypochlorite 0.001%-1%, hypochlorous acid 0.001%-1%, active oxygen 0.001%-0.8%, sodium chloride 0.001%-2%, water.
The present invention provides a kind of method preparing antibacterial anti-adhesion material on the other hand, comprise the following steps: get alginate and be dissolved into aqueous solution, together with sodium chloride solution, put into the electrolyzer that has circulating device, stir, adopt membrane electrolysis to carry out electrolysis, be prepared into antibacterial anti-adhesion material.
According to the concrete example of the present invention, the mass percentage of described alginate solution is 0.5%-10%.
According to the concrete example of the present invention, the mass percentage of described alginate solution is 1.5%-3%.
According to the concrete example of the present invention, the mass percentage of described sodium chloride solution is 0.5%-20%.
According to the concrete example of the present invention, the mass percentage of described sodium chloride solution is 1%.
According to the concrete example of the present invention, described electrolysis time is 30-180 minute.
According to the concrete example of the present invention, described electrolysis time is 60 minutes.
According to the concrete example of the present invention, described alginate is sodium alginate, potassium alginate.
Compared with prior art, the present invention sterilizes because of spectrum, degrades completely, can be utilized, be free from side effects to health, use safety by body absorption.
Additional aspect of the present invention and advantage will part provide in the following description, and part will become obvious from the following description, or be recognized by practice of the present invention.
Detailed description of the invention
Below in conjunction with embodiment, embodiment of the present invention are described in detail, but it will be understood to those of skill in the art that the following example only for illustration of the present invention, and should not be considered as limiting scope of the present invention.
Embodiment one
Weigh the aqueous solution that sodium alginate 100g makes 1%, cyclic electrolysis 10 minutes, then stops 120g sodium chloride to add in electrolyzer, and continue by electrolysis 20 minutes, then airtight electrolyzer, heats 120 DEG C, 6 hours time, takes out experimental liquid.After tested
| Title | Content % |
| Guluronic acid | 0.41 |
| Mannuronic acid | 0.37 |
| Available chlorine content | 0.008 |
| Active oxygen | 0.002 |
| Sodium chloride | 0.91 |
Embodiment two
Weigh the aqueous solution that potassium alginate 120g makes 1%, cyclic electrolysis 10 minutes, then stops 100g sodium chloride to add in electrolyzer, and continue by electrolysis 20 minutes, then airtight electrolyzer, heats 120 DEG C, 6 hours time, takes out experimental liquid.After tested
| Title | Content % |
| Guluronic acid | 0.51 |
| Mannuronic acid | 0.48 |
| Available chlorine content | 0.0074 |
| Active oxygen | 0.0021 |
| Sodium chloride | 0.78 |
Embodiment three
Weigh the aqueous solution that potassium alginate 120g makes 1%, cyclic electrolysis 10 minutes, then stops 100g sodium chloride to add in electrolyzer, and continue by electrolysis 20 minutes, then airtight electrolyzer, heats 120 DEG C, 6 hours time, takes out experimental liquid.After tested
| Title | Content % |
| Guluronic acid | 0.1 |
| Mannuronic acid | 0.1 |
| Available chlorine content | 0.002 |
| Active oxygen | 0.001 |
| Sodium chloride | 0.001 |
Embodiment four
Weigh the aqueous solution that potassium alginate 120g makes 1%, cyclic electrolysis 10 minutes, then stops 100g sodium chloride to add in electrolyzer, and continue by electrolysis 20 minutes, then airtight electrolyzer, heats 120 DEG C, 6 hours time, takes out experimental liquid.After tested
| Title | Content % |
| Guluronic acid | 10 |
| Mannuronic acid | 10 |
| Available chlorine content | 2 |
| Active oxygen | 0.8 |
| Sodium chloride | 2 |
Embodiment five
Screening and the effect evaluation method of the product bacteriostatic experiment of the present invention of preparation are as follows:
With product of the present invention, 2.5% sodium benzoate and normal saline are contrast, study 2.5% trial target solution to the fungistatic effect of the antibacterials such as bacillus subtilis.After 24h or 72h cultivates, observe sample liquid to the inhibition of different strain, by vernier caliper measurement inhibition zone size, concrete numerical value is as following table:
This trial target is to the inhibition (antibacterial circle diameter, mm) of antibacterial
| Strain | Product of the present invention | 2.5% sodium benzoate | Normal saline |
| Bacillus subtilis | 0.8 | - | - |
| Escherichia coli | 1.0 | — | — |
| Micrococcus luteus | 1.5 | — | — |
| Staphylococcus aureus | 1.3 | — | — |
From table in, the inhibition zone of micrococcus luteus and staphylococcus aureus is maximum, bacillus subtilis and colibacillary press down
Bacterium circle time it.Illustrate, the growth inhibited effect of this trial target to micrococcus luteus and staphylococcus aureus is the strongest, takes second place to bacillus subtilis and colibacillary growth inhibited effect.Can find out thus: the growth of this trial target to antibacterial all has inhibitory action.Wherein, comparatively obvious to micrococcus luteus and staphylococcus aureus inhibition, bacillus subtilis and Escherichia coli Growth inhibition are comparatively taken second place.
Equally, with 5% sodium benzoate and normal saline for contrast, study 5% trial target solution to the inhibitory action of the funguses such as skin ulcer tinea bacterium, aspergillosis, candidiasis,
Experimental data is as following table:
This trial target is to the inhibition (antibacterial circle diameter, mm) of fungus
| Strain | Product of the present invention | 5% sodium benzoate | Normal saline |
| Trichophyton mentagrophytes | 1.8 | — | — |
| Aspergillus niger | 1.6 | — | — |
| Candidiasis | 1.30 | — | — |
Show by table: this trial target solution all has inhibitory action to trichophyton mentagrophytes, aspergillosis, candidiasis.
And matched group PhCOONa solution and normal saline are to the equal unrestraint effect of growth of antibacterial and fungus.
Conclusion, no matter be Gram-negative or positive bacteria, this trial target in the present invention can effectively suppress it to grow as antibacterial, shows broad spectrum antibiotic activity.
Embodiment six
Be that the main acute inflammation in animals model changed further illustrates this trial target to acutely inflamed inhibitory action and effect with vascular permeability by setting up.
1, this trial target xylol causes the anti-inflammatory effects of mice ear
Get mice 50, male and female half and half, be divided into 5 groups at random, often organize 10, support a period of time temporarily, after conforming, start experiment.1st group of neck dorsal sc injection physiological saline solution, as negative control group; 2nd group of injected dose is the hydrocortisone Diluted Alcohol solution of 25mg/kg Mus body weight, as the positive-matched group; 3rd, 4,5 groups respectively injected dose be this trial target solution of 50mg/kg, l00mg/kg, 200mg/kg Mus body weight, injection volume is every 0.5ml.Each group of respectively administration in a day on pretreatment, after experimental day respectively organizes administration 1.5h, before and after every mouse right ear two sides respectively even spread dimethylbenzene 0.02ml cause inflammation.After causing inflammation about 1h, by lethal for mice cervical dislocation, cut two ears along auricle baseline, with diameter 6mm card punch respectively two ears same-position lays round auricle, weighs, and is accurate to 0.000lg.The weight difference of auris dextra sheet and left auricle is swelling, inhibitory rate of intumesce computing formula
As follows: suppression ratio (%)=100 × (the average swelling of matched group average swelling one administration group is given up) average swelling of/matched group.Swollen
Swollen thickness Analysis of variance, compares administration group and normal saline group group difference.
2, this trial target gets rat 21, male and female half and half to the anti-inflammatory effects evaluation that Ovum Gallus domesticus album causes rat foot claw swelling, is divided into 3 groups at random, often organizes 7, supports a period of time temporarily.1st group of right abdominal part hypodermic physiological saline solution, as negative control group; 2nd group of injected dose is the hydrocortisone Diluted Alcohol solution of 25ml/kg Mus body weight, as positive controls; 3rd group of injected dose is this trial target solution of 80mk/kg Mus body weight, and injection volume is every 1.3ml.
Each group of respectively administration in a day on pretreatment, experimental day is respectively organized after administration is about 2h, injects the clear 0.1ml(normal saline of 10% Fresh Egg at every Rat Right metapedes sole of the foot).30min, 1.5h, 2.5h, 4.5h vernier caliper measurement foot pawl thickness after Yu Zhiyan, observes thickness and to peak time and regression time.So that the difference of sufficient pawl thickness is swelling thickness before and after scorching, thickness reduces percentage rate as suppression ratio, and computing formula is as follows: suppression ratio (%)=100 × (matched group average swelling thickness one administration group average swelling thickness) average swelling thickness of/matched group.Swelling thickness Analysis of variance: compare administration group and normal saline group difference.
Experimental result shows: this prepared trial target obviously can suppress the inflammatory reaction of mice caused by dimethylbenzene xylene ear swelling, and be obvious dose-dependence to the suppression ratio of swelling, inhibitory action increases with the increase of dosage.When sodium alginate raise sugared dosage be l00mg/kg time, suppress the effect of mice caused by dimethylbenzene xylene ear swelling to be better than the hydrocortisone that dosage is 25mg/kg.This trial target causes rat foot claw swelling to Ovum Gallus domesticus album inhibitory action, and general effect is lower than hydrocortisone, and when the time reaches 4.5h, suppression ratio is suitable with hydrocortisone, and inhibitory action is more lasting.
In a word, this trial target has antiinflammatory action to acute inflammation in animals model and buckles certain analgesic activity, for clinical research provides experimental basis.
The absorbability and the safety that further illustrate this trial target with surrounding tissue biocompatibility is observed by implanting Degrading experiment.Carry out subcutaneous implantation by the regulation in GB/T16886.6, observe after 2 weeks, 4 weeks, it is good with surrounding tissue biocompatibility that result shows this experimental products.
Above about specific descriptions of the present invention, the technical scheme that embodiment of the present invention rope describes only not is limited to for illustration of the present invention, those of ordinary skill in the art should be appreciated that and still can modify to the present invention or equivalent replacement, has reached constructed effect; Needs are used, all within protection scope of the present invention as long as meet.
Claims (1)
1. the preparation method of an antibacterial anti-adhesion material, it is characterized in that, comprise the following steps: weigh the aqueous solution that potassium alginate 120g makes 1%, cyclic electrolysis 10 minutes, then stops, 100g sodium chloride is added in electrolyzer, continue electrolysis 20 minutes, then airtight electrolyzer, heats 120 DEG C, 6 hours time, to obtain final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310219258.6A CN103341215B (en) | 2013-06-04 | 2013-06-04 | A kind of antibacterial anti-adhesion material and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310219258.6A CN103341215B (en) | 2013-06-04 | 2013-06-04 | A kind of antibacterial anti-adhesion material and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103341215A CN103341215A (en) | 2013-10-09 |
| CN103341215B true CN103341215B (en) | 2016-03-02 |
Family
ID=49276073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310219258.6A Active CN103341215B (en) | 2013-06-04 | 2013-06-04 | A kind of antibacterial anti-adhesion material and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103341215B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1379623A (en) * | 1999-10-21 | 2002-11-13 | 方济各安吉利克化学联合股份有限公司 | Topical, non-cytotoxic, antimicrobial hydrogel with thixotropic properties |
| CN1981881A (en) * | 2005-12-14 | 2007-06-20 | 四川琢新生物材料研究有限公司 | Materials against bonding after surgical operation |
| CN101037456A (en) * | 2007-04-24 | 2007-09-19 | 宁波大学 | Preparation method of alginate oligosaccharides |
| CN102844035A (en) * | 2010-03-11 | 2012-12-26 | 本德尔分析控股有限公司 | Sterile alginate-based aqueous composition for medical use and process for the preparation thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070027107A1 (en) * | 2005-07-29 | 2007-02-01 | Curt Hendrix | Compositions and methods for treating estrogen-dependent diseases and conditions |
| AU2008266060B2 (en) * | 2007-06-13 | 2013-08-29 | Fmc Corporation | Alginate coated, polysaccharide gel-containing foam composite, preparative methods, and uses thereof |
-
2013
- 2013-06-04 CN CN201310219258.6A patent/CN103341215B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1379623A (en) * | 1999-10-21 | 2002-11-13 | 方济各安吉利克化学联合股份有限公司 | Topical, non-cytotoxic, antimicrobial hydrogel with thixotropic properties |
| CN1981881A (en) * | 2005-12-14 | 2007-06-20 | 四川琢新生物材料研究有限公司 | Materials against bonding after surgical operation |
| CN101037456A (en) * | 2007-04-24 | 2007-09-19 | 宁波大学 | Preparation method of alginate oligosaccharides |
| CN102844035A (en) * | 2010-03-11 | 2012-12-26 | 本德尔分析控股有限公司 | Sterile alginate-based aqueous composition for medical use and process for the preparation thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103341215A (en) | 2013-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20150264935A1 (en) | Semi-Fluidic Composition for Lubricating, Moisture Retaining, Disinfecting, Sterilizing and Method Using the Same | |
| CN102824308B (en) | Chitosan antibacterial filming sprayer and preparation method | |
| CN105055304A (en) | Leave-on skin care and disinfection gel containing composite sterilization component, and preparation method thereof | |
| CN105168239B (en) | A kind of breast protecting film and its preparation process for being used to prevent mastitis for milk cows | |
| CN110123832A (en) | A kind of ophthalmic composition containing no drug resistance fungicide | |
| CN108042578A (en) | A kind of health care vaginal jellies containing compound probiotic ingredient | |
| CN111449973A (en) | Foaming agent for restoring microecological balance of female vagina and preparation method thereof | |
| CN101543658B (en) | Cervical cap for preventing and treating cervical erosion and preparation method thereof | |
| CN102405935B (en) | Protamine compounded preparation, preparation method and application thereof | |
| CN104586899B (en) | A kind of aerosol and preparation method thereof for treating bedsore | |
| CN111991417A (en) | Hypochlorous acid gel with physiological responsiveness and application thereof in skin wound surface | |
| CN104667267A (en) | Lysozyme compound agent for skin external use and preparation method of lysozyme compound agent | |
| CN103341215B (en) | A kind of antibacterial anti-adhesion material and preparation method thereof | |
| CN106267329A (en) | A kind of plants essential oil gel dressing and its preparation method and application | |
| CN107412257B (en) | Medicated bath agent for nipples of dairy cows as well as preparation method and application of medicated bath agent | |
| CN103285032A (en) | Medicine composition for preventing and treating fungal disease of pet rabbit | |
| CN108096276A (en) | A kind of debridement healing washing lotion and its application | |
| CN106237029B (en) | A kind of aloe antibiotic gel and preparation method thereof | |
| CN101816678A (en) | Broad-spectrum contact type hemostatic medical fungicide and preparation method thereof | |
| CN109200137A (en) | A kind of tea oil bacteriostatic agent and preparation method thereof | |
| CN106265720A (en) | A kind of combined artificial tear and preparation method thereof | |
| CN109200326A (en) | Dressing and bandage for wound healing | |
| CN108079050A (en) | Herbal skin bacteria inhibiting composition and preparation method and application | |
| CN107714501A (en) | One kind is without alcohol foam hand sanitizing fluid | |
| CN102697786A (en) | Urotropine composite skin disinfectant and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210826 Address after: 117000 No. 69, Xianghuai Road, economic and Technological Development Zone, Benxi City, Liaoning Province Patentee after: Liaoning Didong Pharmaceutical Bioengineering Co.,Ltd. Address before: 266000 household 1106, unit 2, No. 114, Yan'an Third Road, Shibei District, Qingdao City, Shandong Province Patentee before: QINGDAO ZHONGTENG BIOTECHNOLOGY Co.,Ltd. |